title: [KIMS observational study of GH therapy in GH-deficient adults: 12-month follow-up analysis of the French cohort].
abstract: KIMS study is an international, observational study initiated in 1994 in which France has been involved since 2003. Its aim is to collect on a widespread basis long-term data from GH-deficient adults treated or not treated with growth hormone in daily practice. Among 330 patients already enrolled by 128 centers in France at the data lock point for this first interim analysis, 122 patients were followed up for at least 12 months and their results are presented herein. After one year of treatment, IGF-1 level adjusted for age and sex was normalized for 77% of patients naive of GH-treatment, 71% of semi-naive patients and 85% of non naive patients. Lean mass increase was 5.1% and fat mass decrease 5.7%. Quality of life assessed through QoL-AGHDA questionnaire was improved with a median score decrease from 10 to 6. These are the first results available from French patients and suggest that growth hormone is an appropriate indication for adults with severe GH deficiency.
authors.affiliation: Service d'Endocrinologie, Diabète et Maladies Métaboliques, Hôpital de la Timone, 264 rue Saint-Pierre, 13385 Marseille cedex 05.
authors.forename: T
authors.initials: T
authors.lastname: Brue
authors.forename: F
authors.initials: F
authors.lastname: Borson-Chazot
authors.forename: B
authors.initials: B
authors.lastname: Delemer
authors.forename: J-L
authors.initials: JL
authors.lastname: Schlienger
authors.forename: A
authors.initials: A
authors.lastname: Chachuat
authors.forename: I
authors.initials: I
authors.lastname: Pion
authors.forename: P
authors.initials: P
authors.lastname: Touraine
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005500:Follow-Up Studies; D005602:France; D013006:Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D013006:Growth Hormone